Obesity Treatment in the UK 2026:
Your Options

Understanding obesity as a medical condition

Obesity is recognised by NICE, the World Health Organization and the Royal College of Physicians as a chronic, progressive disease — not simply a lifestyle choice. It involves complex interactions between genetics, metabolic processes, hormonal regulation, environmental factors and behaviour. This recognition is important because it underpins the clinical rationale for medical and surgical treatments alongside lifestyle interventions.

In the UK, obesity is associated with more than 200 comorbidities including type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, certain cancers, osteoarthritis and non-alcoholic fatty liver disease. Effective treatment can substantially reduce the risk of these conditions and improve quality of life.

The NHS tiered pathway for obesity

The NHS in England uses a structured four-tier pathway for the management of obesity. Understanding this system helps you know what support is available and how to access more intensive treatments.

Tier 1: universal services

Tier 1 encompasses public health and community-level interventions available to the general population. These include:

• Health promotion campaigns (Change4Life, Better Health)
• NHS Health Checks for adults aged 40–74
• Brief interventions by GPs and practice nurses
• Community weight management programmes

Tier 2: lifestyle and behavioural interventions

Tier 2 services are structured weight management programmes delivered in community or primary care settings. They typically include:

• 12-week group or digital programmes (e.g. Second Nature, which is NHS-commissioned in 43 ICBs)
• Dietary advice from trained practitioners
• Physical activity programmes
• Behavioural change support

Referral is usually via your GP or self-referral, depending on the local area. NICE recommends Tier 2 as the foundation for all subsequent treatment.

Tier 3: specialist weight management

Tier 3 services are multidisciplinary specialist programmes, typically run by hospital trusts or commissioned specialist providers. They offer:

• Detailed medical assessment and investigation of secondary causes of obesity
• Specialist dietetics, psychology and physiotherapy input
• Pharmacotherapy including GLP-1 receptor agonists (Wegovy, Mounjaro)
• Preparation and assessment for bariatric surgery if appropriate

Access to Tier 3 typically requires a GP referral. Waiting times vary considerably across England, ranging from weeks to over 12 months depending on the area.

Tier 4: bariatric surgery

Tier 4 is surgical intervention for the most severe cases of obesity. NICE recommends consideration of bariatric surgery for adults who meet the following criteria:

• BMI of 40 or above, or BMI of 35–39.9 with significant obesity-related comorbidities
• All appropriate non-surgical treatments have been tried without achieving clinically meaningful weight loss
• The patient is fit for general anaesthesia and surgery
• The patient commits to long-term follow-up

Common bariatric procedures in the UK include gastric sleeve, gastric bypass and adjustable gastric band. These surgeries produce substantial long-term weight loss (typically 20–35 per cent of total body weight) and are effective at resolving type 2 diabetes and other comorbidities.

When to consider medication

NICE recommends pharmacotherapy for obesity when lifestyle interventions alone have not achieved clinically meaningful weight loss (generally defined as 5 per cent or more of initial body weight). The following medications are currently NICE-approved for weight management in the UK:

The role of GLP-1 medications

GLP-1 receptor agonists and the newer dual GIP/GLP-1 agonists represent the most significant advance in obesity pharmacotherapy in decades. These medications work by mimicking natural gut hormones that regulate appetite, food intake and blood glucose levels.

In 2026, GLP-1-based treatments are increasingly central to the NHS obesity strategy. Key developments include:

• Wegovy for cardiovascular risk reduction: In April 2026, NICE approved semaglutide 2.4 mg for reducing the risk of major adverse cardiovascular events in adults with obesity and established cardiovascular disease, making an estimated 1.2 million additional patients eligible
• Mounjaro NHS expansion: Tirzepatide is now available through specialist services for weight management and through some GP practices for type 2 diabetes
• Private access: All GLP-1 medications are available through private online clinics for patients who do not meet NHS criteria or face long waiting times

For a detailed comparison of available GLP-1 medications, see our UK weight loss injections comparison guide.

Surgery vs medication: how do they compare?

The choice between medication and surgery depends on the severity of obesity, the presence of comorbidities, patient preference, previous treatment history and clinical assessment. In many cases, GLP-1 medication serves as either an alternative to surgery or a bridge treatment whilst awaiting surgical referral.

NICE guidelines: what changed in 2025–2026

The NICE obesity treatment landscape has evolved significantly over the past two years. Key updates include:

• TA875 (2023): Semaglutide 2.4 mg (Wegovy) recommended for weight management in specialist services
• TA1026 (2024): Tirzepatide (Mounjaro) recommended for weight management
• QOF 2026/27: Updated indicators for obesity management in primary care recognising GLP-1 therapies
• April 2026: Wegovy approved for cardiovascular risk reduction (expanding eligibility significantly)
• Ongoing: NICE assessment of oral semaglutide for weight management (decision expected late 2026)

How to access treatment

Through the NHS

1. Visit your GP: Discuss your weight and any related health conditions
2. Referral to Tier 2: Your GP may refer you to a local weight management programme
3. Escalation to Tier 3: If Tier 2 is insufficient, your GP can refer you to specialist services where medication including Wegovy and Mounjaro may be prescribed
4. Tier 4 consideration: Specialist teams assess suitability for bariatric surgery if appropriate

Through private providers

If NHS waiting times are prohibitive or you do not meet NHS criteria, private online clinics such as Numan, Second Nature and Manual offer GLP-1 medication with clinical oversight from £129 per month. All reputable providers are regulated by the Care Quality Commission (CQC).

For information on obtaining an online weight loss prescription, see our dedicated guide.

Frequently asked questions

What BMI do I need to get weight loss treatment on the NHS?

For GLP-1 medications via specialist services, NICE generally requires a BMI of 35 or above (or 30–34.9 with weight-related comorbidities). BMI thresholds are adjusted downwards by 2.5 points for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean descent. For bariatric surgery, a BMI of 40 or above is typically required, or 35–39.9 with significant comorbidities.

Can my GP prescribe weight loss medication directly?

GPs can prescribe orlistat directly. For GLP-1 medications, prescribing for weight management typically requires initiation through Tier 3 specialist services. However, GPs can prescribe Mounjaro for type 2 diabetes under NICE guidance. Some areas operate shared care arrangements where GPs continue prescribing after specialist initiation.

Is obesity surgery available on the NHS?

Yes, bariatric surgery is available on the NHS for patients who meet NICE criteria. However, access varies significantly by area and waiting times can exceed two years. The number of NHS bariatric procedures has increased since 2023 following updated NICE guidance, but demand still far exceeds capacity.